Last updateTue, 05 Dec 2023 9am

Back You are here: Inicio Biology & biomedicine

Knowledge-based companies to cross the Valley of Death

30 years of R+D CSIC

Knowledge-based companies help to bring scientific results from research centres to the market and society. Thirty years ago, none existed at the CSIC. Since 1999, the CSIC has promoted about 170 companies. Of these, around 60% are still active.

Read more ...

Antibodies against Alzheimer's disease

Scientists at the Centre for Molecular Biology (CBM), joint center of the CSIC and the UAM, have developed antibodies that neutralise the SFRP1 protein, which according to recent studies is a crucial player in the pathogenesis of Alzheimer's disease and a promising therapeutic target. The aim is to obtain a drug that can delay the progression of the disease. Now they are searching for partners to scale-up the trial for clinical use.

Read more ...

New method for the detection of RNA viruses such as SARS-CoV-2

This new methodology is effective and faster than the PCR test, and opens up new options for detecting viruses such as SARS-CoV-2, the influenza A virus (H1N1) or the respiratory syncytial virus (RSV), a pathogen that affects newborn babies and requires careful differential diagnosis.

Read more ...

JEMCA, electron microscopy to advance research in structural biology and new materials

It is a pioneering facility that houses two high-end electron microscopes: one to resolve the structure of large protein and nucleic acid complexes and the other to study materials at the atomic scale. Created thanks to the joint action of several research institutions, including the CSIC, it is located at the ALBA Synchrotron (Cerdanyola, Barcelona) and is open to the entire scientific community.

Read more ...

Hydrogels for growing immune cells and mini-organs

A scientific team has developed new hydrogels that serve as 3D culture systems for immune cells and organoids. They allow a higher rate of cell growth than traditional cultures. Among other applications, the team is focusing on growing cells for immunotherapies and obtaining mini-organs for pre-clinical trials.

Read more ...